Strides Arcolab Enters Licensing Agreement to Manufacture Antiretroviral TAF Treatment
India-based manufacturers - Aurobindo, Cipla, Emcure, Hetero, and Laursus Laboratories (as well as China's Desano) - to manufacture and market the product in the same 112 low- and middle-income countries. Mylan (US) has received similar non-exclusive rights. Gilead Sciences announced positive Phase III clinical trials data for TAF in September 2014 related to the safety and efficacy of the once-daily single-tablet dose of the treatment. Clinical trials have also favourably compared TAF as a combination treatment versus Stribild (elvitegravir; seeUnited States: 25 September 2014:). The results also demonstrated non-inferiority of TAF at 10 times lower doses compared with Viread (tenofovir disoproxil fumarate) with the same active ingredient.